Special considerations for the diagnosis and treatment of invasive pulmonary aspergillosis

References

• McCarthy MW, Aguilar-Zapata D, Petraitis V, et al. Diagnosis, classification, and therapeutic interventions for sinopulmonary aspergillosis. Expert Rev Respir Med. 2017;11(3):229–238.
   PubMed Web of Science ®Google Scholar
• Menz G, Willer G, Crameri R. Allergic bronchopulmonary aspergillosis (ABPA). Pneumologie. 2000;54(9):375–384.
   PubMedGoogle Scholar
• De Soyza A, Aliberti S. Bronchiectasis and Aspergillus: how are they linked? Med Mycol. 2016;55:69–81.
   PubMed Web of Science ®Google Scholar
• Segal BH. Aspergillosis. N Engl J Med. 2009;360(18):1870–1884.
   Google Scholar
• Hagiwara D, Watanabe A, Kamei K, et al. Epidemiological and genomic landscape of azole resistance mechanisms in Aspergillus fungi. Front Microbiol. 2016;7:1382.
   PubMed Web of Science ®Google Scholar
• Shaukat A, Bakri F, Young P, et al. Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: clinical, radiologic, and pathologic characteristics. Mycopathologia. 2005;159(2):181–188.
   PubMed Web of Science ®Google Scholar
• Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1–e60.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327–360.
   PubMed Web of Science ®Google Scholar
• Lanternier F, Mahdaviani SA, Barbati E, et al. Inherited CARD9 deficiency in otherwise healthy children and adults with Candida species-induced meningoencephalitis, colitis, or both. J Allergy Clin Immunol. 2015;135(6):1558–68.e2.
   PubMed Web of Science ®Google Scholar
• Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. Thorax. 2015;70(3):270–277.
   PubMed Web of Science ®Google Scholar
• Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102(3):433–444.
   PubMed Web of Science ®Google Scholar
• Jaumally BA, Salem AM, Sagar AE, et al. Invasive pulmonary aspergillosis in a steroid-dependent asthmatic. Respir Med Case Rep. 2017;20:156–159.
   PubMed Web of Science ®Google Scholar
• Marti Aguado D, Ballester MP, Bosca Watts MM. Invasive pulmonary aspergillosis in an immunocompromised patient with severe ulcerative colitis. Rev Esp Enferm Dig. 2017;109:316–317.
   Web of Science ®Google Scholar
• Lowes D, Al-Shair K, Newton PJ, et al. Predictors of mortality in chronic pulmonary aspergillosis. Eur Respir J. 2017;49(2):1601062.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Bansal S, Chakrabarti A. Are allergic fungal rhinosinusitis and allergic bronchopulmonary aspergillosis lifelong conditions? Med Mycol. 2016;87–95.
   PubMed Web of Science ®Google Scholar
• Fernandes L, Estibeiro AS, Mesquita AM. Hypersensitivity pneumonitis in a housewife exposed to Aspergillus flavus in poor living conditions: a case report. J Clin Diagn Res. 2016;10(1):OD16–7.
   PubMed Web of Science ®Google Scholar
• Garg MK, Sharma M, Agarwal R, et al. Allergic bronchopulmonary aspergillosis: Alla radiologist needs to know. Curr Pediatr Rev. 2016;12(3):179–189.
   PubMedGoogle Scholar
• Sharma BB, Singh S, Singh V. Hypersensitivity pneumonitis: the dug-well lung. Allergy Asthma Proc. 2013;34(6):e59–64.
   PubMed Web of Science ®Google Scholar
• Denning DW, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J. 2016;47(1):45–68.
   PubMed Web of Science ®Google Scholar
• Daley GQ. Polar extremes in the clinical use of stem cells. N Engl J Med. 2017;376(11):1075–1077.
   PubMed Web of Science ®Google Scholar
• Denning DW, Perlin DS, Muldoon EG, et al. Delivering on antimicrobial resistance agenda not possible without improving fungal diagnostic capabilities. Emerg Infect Dis. 2017;23(2):177–183.
   PubMed Web of Science ®Google Scholar
• McCarthy M, Rosengart A, Schuetz AN, et al. Mold infections of the central nervous system. N Engl J Med. 2014;371(2):150–160.
   PubMed Web of Science ®Google Scholar
• Patterson TF, Thompson GR, Denning DW, et al. Executive summary: practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):433–442.
   PubMed Web of Science ®Google Scholar
• Stergiopoulou T, Meletiadis J, Roilides E, et al. Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis. Am J Clin Pathol. 2007;127(3):349–355.
   PubMed Web of Science ®Google Scholar
• Azoulay E, Afessa B. Diagnostic criteria for invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med. 2012;186(1):8–10.
   PubMed Web of Science ®Google Scholar
• Borlenghi E, Cattaneo C, Capucci MA, et al. Usefulness of the MSG/IFICG/EORTC diagnostic criteria of invasive pulmonary aspergillosis in the clinical management of patients with acute leukaemia developing pulmonary infiltrates. Ann Hematol. 2007;86(3):205–210.
   PubMed Web of Science ®Google Scholar
• Aller-García AI, Castro-Méndez C, Alastruey-Izquierdo A, et al. Case series study of invasive pulmonary aspergillosis. Mycopathologia. 2016;182:505–515.
   PubMed Web of Science ®Google Scholar
• McCarthy MW, Petraitiene R, Walsh TJ. Nucleic acid amplification methodologies for the detection of pulmonary mold infections. Expert Rev Mol Diagn. 2017;17(3):271–279.
   PubMed Web of Science ®Google Scholar
• Wattal C, Oberoi JK, Goel N, et al. Matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) for rapid identification of micro-organisms in the routine clinical microbiology laboratory. Eur J Clin Microbiol Infect Dis. 2016;36:807–812.
   PubMed Web of Science ®Google Scholar
• Reinwald M, Spiess B, Heinz WJ, et al. Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an Aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples. Eur J Haematol. 2012;89(2):120–127.
   PubMed Web of Science ®Google Scholar
• Verdaguer V, Walsh TJ, Hope W, et al. Galactomannan antigen detection in the diagnosis of invasive aspergillosis. Expert Rev Mol Diagn. 2007;7(1):21–32.
   PubMed Web of Science ®Google Scholar
• Machetti M, Viscoli C. [Interactions and false positive results of galactomannan antigen detection for diagnosis of invasive aspergillosis]. Infez Med. 2006;14(4):197–207.
   PubMedGoogle Scholar
• Sulahian A, Tabouret M, Ribaud P, et al. Comparison of an enzyme immunoassay and latex agglutination test for detection of galactomannan in the diagnosis of invasive aspergillosis. Eur J Clin Microbiol Infect Dis. 1996;15(2):139–145.
   PubMed Web of Science ®Google Scholar
• Bart-Delabesse E, Basile M, Al Jijakli A, et al. Detection of Aspergillus galactomannan antigenemia to determine biological and clinical implications of beta-lactam treatments. J Clin Microbiol. 2005;43(10):5214–5220.
   PubMed Web of Science ®Google Scholar
• Marr KA, Leisenring W. Design issues in studies evaluating diagnostic tests for aspergillosis. Clin Infect Dis. 2005;41(Suppl 6):S381–6.
   PubMed Web of Science ®Google Scholar
• Verweij PE, Brinkman K, Kremer HP, et al. Aspergillus meningitis: diagnosis by non-culture-based microbiological methods and management. J Clin Microbiol. 1999;37(4):1186–1189.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Shoham S, Petraitiene R, et al. Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction. J Clin Microbiol. 2004;42(10):4744–4748.
   PubMed Web of Science ®Google Scholar
• Klont RR, Mennink-Kersten MA, Verweij PE. Utility of Aspergillus antigen detection in specimens other than serum specimens. Clin Infect Dis. 2004;39(10):1467–1474.
   PubMed Web of Science ®Google Scholar
• Machetti M, Zotti M, Veroni L, et al. Antigen detection in the diagnosis and management of a patient with probable cerebral aspergillosis treated with voriconazole. Transpl Infect Dis. 2000;2(3):140–144.
   PubMedGoogle Scholar
• Eigl S, Prattes J, Reinwald M, et al. Influence of mould-active antifungal treatment on the performance of the Aspergillus-specific bronchoalveolar lavage fluid lateral-flow device test. Int J Antimicrob Agents. 2015;46(4):401–405.
   PubMed Web of Science ®Google Scholar
• Duarte RF, Sánchez-Ortega I, Cuesta I, et al. Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. Clin Infect Dis. 2014;59(12):1696–1702.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Chanock SJ. Diagnosis of invasive fungal infections: advances in nonculture systems. Curr Clin Top Infect Dis. 1998;18:101–153.
   PubMedGoogle Scholar
• Miyazaki T, Kohno S, Mitsutake K, et al. Plasma (1–>3)-beta-D-glucan and fungal antigenemia in patients with candidemia, aspergillosis, and cryptococcosis. J Clin Microbiol. 1995;33(12):3115–3118.
   PubMed Web of Science ®Google Scholar
• Kawazu M, Kanda Y, Nannya Y, et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1–>3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol. 2004;42(6):2733–2741.
   PubMed Web of Science ®Google Scholar
• Kanamori H, Kanemitsu K, Miyasaka T, et al. Measurement of (1-3)-beta-D-glucan derived from different gauze types. Tohoku J Exp Med. 2009;217(2):117–121.
   PubMed Web of Science ®Google Scholar
• Pickering JW, Sant HW, Bowles CA, et al. Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol. 2005;43(12):5957–5962.
   PubMed Web of Science ®Google Scholar
• Cuétara MS, Alhambra A, Moragues MD, et al. Detection of (1–>3)-beta-D-glucan as an adjunct to diagnosis in a mixed population with uncommon proven invasive fungal diseases or with an unusual clinical presentation. Clin Vaccine Immunol. 2009;16(3):423–426.
   PubMed Web of Science ®Google Scholar
• Cornu M, Goudjil S, Kongolo G, et al. Evaluation of the (1,3)-β-D-glucan assay for the diagnosis of neonatal invasive yeast infections. Med Mycol. 2017.
   PubMedGoogle Scholar
• Marr KA, Laverdiere M, Gugel A, et al. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis. 2005;40(12):1762–1769.
   PubMed Web of Science ®Google Scholar
• Hoenigl M, Seeber K, Koidl C, et al. Sensitivity of galactomannan enzyme immunoassay for diagnosing breakthrough invasive aspergillosis under antifungal prophylaxis and empirical therapy. Mycoses. 2013;56(4):471–476.
   PubMed Web of Science ®Google Scholar
• Sulahian A, Porcher R, Bergeron A, et al. Use and limits of (1-3)-β-d-glucan assay (Fungitell), compared to galactomannan determination (Platelia Aspergillus), for diagnosis of invasive aspergillosis. J Clin Microbiol. 2014;52(7):2328–2333.
   PubMed Web of Science ®Google Scholar
• McCarthy MW, Walsh TJ. PCR methodology and applications for the detection of human fungal pathogens. Expert Rev Mol Diagn. 2016;16(9):1025–1036.
   PubMed Web of Science ®Google Scholar
• Masih A, Singh PK, Kathuria S, et al. Identification by molecular methods and matrix-assisted laser desorption ionization-time of flight mass spectrometry and antifungal susceptibility profiles of clinically significant rare aspergillus species in a referral chest hospital in Delhi, India. J Clin Microbiol. 2016;54(9):2354–2364.
   PubMed Web of Science ®Google Scholar
• Reinwald M, Hummel M, Kovalevskaya E, et al. Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies. J Antimicrob Chemother. 2012;67(9):2260–2267.
   PubMed Web of Science ®Google Scholar
• Bretagne S, Costa JM, Bart-Delabesse E, et al. Comparison of serum galactomannan antigen detection and competitive polymerase chain reaction for diagnosing invasive aspergillosis. Clin Infect Dis. 1998;26(6):1407–1412.
   PubMed Web of Science ®Google Scholar
• Donnelly JP. Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a ways to go. Clin Infect Dis. 2006;42(4):487–489.
   PubMed Web of Science ®Google Scholar
• White PL, Mengoli C, Bretagne S, et al. Evaluation of Aspergillus PCR protocols for testing serum specimens. J Clin Microbiol. 2011;49(11):3842–3848.
   PubMed Web of Science ®Google Scholar
• White PL, Perry MD, Loeffler J, et al. Critical stages of extracting DNA from Aspergillus fumigatus in whole-blood specimens. J Clin Microbiol. 2010;48(10):3753–3755.
   PubMed Web of Science ®Google Scholar
• Arvanitis M, Ziakas PD, Zacharioudakis IM, et al. PCR in diagnosis of invasive aspergillosis: a meta-analysis of diagnostic performance. J Clin Microbiol. 2014;52(10):3731–3742.
   PubMed Web of Science ®Google Scholar
• White PL, Barnes RA, Springer J, et al. Clinical performance of Aspergillus PCR for testing serum and plasma: a study by the European Aspergillus PCR Initiative. J Clin Microbiol. 2015;53(9):2832–2837.
   PubMed Web of Science ®Google Scholar
• Oz Y, Aslan M, Aksit F, et al. The effect of clinical characteristics on the performance of galactomannan and PCR for the diagnosis of invasive aspergillosis in febrile neutropenic patients. Mycoses. 2016;59(2):86–92.
   PubMed Web of Science ®Google Scholar
• Aslan M, Oz Y, Aksit F, et al. Potential of polymerase chain reaction and galactomannan for the diagnosis of invasive aspergillosis in patients with febrile neutropenia. Mycoses. 2015;58(6):343–349.
   PubMed Web of Science ®Google Scholar
• Guinea J, Padilla C, Escribano P, et al. Evaluation of MycAssay™ Aspergillus for diagnosis of invasive pulmonary aspergillosis in patients without hematological cancer. Plos One. 2013;8(4):e61545.
   PubMed Web of Science ®Google Scholar
• Cruciani M, Mengoli C, Loeffler J, et al. Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people. Cochrane Database Syst Rev. 2015;10:CD009551.
   Google Scholar
• Arvanitis M, Anagnostou T, Fuchs BB, et al. Molecular and nonmolecular diagnostic methods for invasive fungal infections. Clin Microbiol Rev. 2014;27(3):490–526.
   PubMed Web of Science ®Google Scholar
• Becker PT, De Bel A, Martiny D, et al. Identification of filamentous fungi isolates by MALDI-TOF mass spectrometry: clinical evaluation of an extended reference spectra library. Med Mycol. 2014;52(8):826–834.
   PubMed Web of Science ®Google Scholar
• Yonetani S, Ohnishi H, Ohkusu K, et al. Direct identification of microorganisms from positive blood cultures by MALDI-TOF MS using an in-house saponin method. Int J Infect Dis. 2016;52:37–42.
   PubMed Web of Science ®Google Scholar
• Idelevich EA, Grünastel B, Becker K. Rapid detection and identification of candidemia by direct blood culturing on solid medium using lysis-centrifugation method combined with MALDI-TOF MS. J Clin Microbiol. 2016;55:97–100.
   PubMed Web of Science ®Google Scholar
• Mery A, Sendid B, François N. Application of mass spectrometry technology to the early diagnosis of invasive fungal infections. J Clin Microbiol. 2016;54:2786–2797.
   PubMed Web of Science ®Google Scholar
• Nakamura S, Sato H, Tanaka R, et al. Ribosomal subunit protein typing using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) for the identification and discrimination of Aspergillus species. BMC Microbiol. 2017;17(1):100.
   PubMed Web of Science ®Google Scholar
• Enoch DA, Yang H, Aliyu SH, et al. The changing epidemiology of invasive fungal infections. Methods Mol Biol. 2017;1508:17–65.
   PubMedGoogle Scholar
• Leonardelli F, Theill L, Nardin ME, et al. First itraconazole resistant Aspergillus fumigatus clinical isolate harbouring a G54E substitution in Cyp51Ap in South America. Rev Iberoam Micol. 2017;34(1):46–48.
   PubMed Web of Science ®Google Scholar
• Zhang M, Feng CL, Chen F, et al. Triazole resistance in Aspergillus fumigatus clinical isolates obtained in Nanjing, China. Chin Med J (Engl). 2017;130(6):665–668.
   PubMed Web of Science ®Google Scholar
• Kimura S. Invasive aspergillosis in hematological patients. Med Mycol J. 2016;57(2):J77–88.
   PubMedGoogle Scholar
• Cornely OA, Schmitz K, Aisenbrey S. The first echinocandin: caspofungin. Mycoses. 2002;45(Suppl 3):56–60.
   PubMed Web of Science ®Google Scholar
• Maertens JA, Blennow O, Duarte RF, et al. The current management landscape: aspergillosis. J Antimicrob Chemother. 2016;71(suppl 2):ii23-ii29.
   PubMed Web of Science ®Google Scholar
• Graves B, Morrissey CO, Wei A, et al. Isavuconazole as salvage therapy for mucormycosis. Med Mycol Case Rep. 2016;11:36–39.
   PubMed Web of Science ®Google Scholar
• Natesan SK, Chandrasekar PH. Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations. Infect Drug Resist. 2016;9:291–300.
   PubMed Web of Science ®Google Scholar
• Donnelley MA, Zhu ES, Thompson GR. Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections. Infect Drug Resist. 2016;9:79–86.
   PubMed Web of Science ®Google Scholar
• Desai A, Schmitt-Hoffmann AH, Mujais S, et al. Population pharmacokinetics of isavuconazole in subjects with mild or moderate hepatic impairment. Antimicrob Agents Chemother. 2016;60(5):3025–3031.
   PubMed Web of Science ®Google Scholar
• Desai A, Yamazaki T, Dietz AJ, et al. Pharmacokinetic and pharmacodynamic evaluation of the drug-drug interaction between isavuconazole and warfarin in healthy subjects. Clin Pharmacol Drug Dev. 2016;9:291–300.
   Google Scholar
• Warn PA, Sharp A, Denning DW. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J Antimicrob Chemother. 2006;57(1):135–138.
   PubMed Web of Science ®Google Scholar
• Lepak AJ, Marchillo K, Vanhecker J, et al. Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus. Antimicrob Agents Chemother. 2013;57(12):6284–6289.
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Roos B, Maares J, et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug,BAL8557, in healthy volunteers. Antimicrob Agents Chemother. 2006;50(1):286–293.
   PubMed Web of Science ®Google Scholar
• Guinea J, Peláez T, Recio S, et al. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of Zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother. 2008;52(4):1396–1400.
   PubMed Web of Science ®Google Scholar
• Rybak JM, Marx KR, Nishimoto AT, et al. Isavuconazole: pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent. Pharmacotherapy. 2015;35(11):1037–1051.
   PubMed Web of Science ®Google Scholar
• Pettit NN, Carver PL. Isavuconazole: a new option for the management of invasive fungal infections. Ann Pharmacother. 2015;49(7):825–842.
   PubMed Web of Science ®Google Scholar
• Livermore J, Hope W. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. Expert Opin Drug Metab Toxicol. 2012;8(6):759–765.
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Desai A, Kowalski D, et al. Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH. Int J Clin Pharmacol Ther. 2016;54(8):572–580.
   PubMed Web of Science ®Google Scholar
• Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760–769.
   PubMed Web of Science ®Google Scholar
• Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828–837.
   PubMed Web of Science ®Google Scholar
• Shirley M, Scott LJ. Isavuconazole: a review in invasive aspergillosis and mucormycosis. Drugs. 2016;76:1647–1657.
   PubMed Web of Science ®Google Scholar
• Kovanda LL, Petraitiene R, Petraitis V, et al. Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints. J Antimicrob Chemother. 2016;71(7):1885–1891.
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Roos B, Heep M, et al. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother. 2006;50(1):279–285.
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Roos B, Spickermann J, et al. Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557. Antimicrob Agents Chemother. 2009;53(11):4885–4890.
   PubMed Web of Science ®Google Scholar
• Kovanda LL, Desai AV, Lu Q, et al. Isavuconazole population pharmacokinetic analysis using nonparametric estimation in patients with invasive fungal disease (results from the VITAL study). Antimicrob Agents Chemother. 2016;60(8):4568–4576.
   PubMed Web of Science ®Google Scholar
• Miceli MH, Kauffman CA. Isavuconazole: a new broad-spectrum triazole antifungal agent. Clin Infect Dis. 2015;61(10):1558–1565.
   PubMed Web of Science ®Google Scholar
• Desai A, Kovanda L, Kowalski D, et al. Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to aspergillus and other filamentous fungi. Antimicrob Agents Chemother. 2016;60(9):5483–5491.
   PubMed Web of Science ®Google Scholar
• Arvanitis M, Anagnostou T, Mylonakis E. Galactomannan and polymerase chain reaction-based screening for invasive aspergillosis among high-risk hematology patients: a diagnostic meta-analysis. Clin Infect Dis. 2015;61(8):1263–1272.
   PubMed Web of Science ®Google Scholar
• Aguado JM, Vázquez L, Fernández-Ruiz M, et al. Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based Aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: a randomized controlled trial. Clin Infect Dis. 2015;60(3):405–414.
   PubMed Web of Science ®Google Scholar
• Denning DW. Calling upon all public health mycologists: to accompany the country burden papers from 14 countries. Eur J Clin Microbiol Infect Dis. 2017;36:923–924.
   PubMed Web of Science ®Google Scholar
• Hoenigl M, Koidl C, Duettmann W, et al. Bronchoalveolar lavage lateral-flow device test for invasive pulmonary aspergillosis diagnosis in haematological malignancy and solid organ transplant patients. J Infect. 2012;65(6):588–591.
   PubMed Web of Science ®Google Scholar
• Prattes J, Lackner M, Eigl S, et al. Diagnostic accuracy of the Aspergillus-specific bronchoalveolar lavage lateral-flow assay in haematological malignancy patients. Mycoses. 2015;58(8):461–469.
   PubMed Web of Science ®Google Scholar
• Pan Z, Fu M, Zhang J, et al. Diagnostic accuracy of a novel lateral-flow device in invasive aspergillosis: a meta-analysis. J Med Microbiol. 2015;64(7):702–707.
   PubMed Web of Science ®Google Scholar
• Johnson GL, Sarker SJ, Nannini F, et al. Aspergillus-specific lateral-flow device and real-time PCR testing of bronchoalveolar lavage fluid: a combination biomarker approach for clinical diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol. 2015;53(7):2103–2108.
   PubMed Web of Science ®Google Scholar
• Osherov N, Kontoyiannis DP. The anti-Aspergillus drug pipeline: is the glass half full or empty? Med Mycol. 2016;55:118–124.
   PubMed Web of Science ®Google Scholar
• Miyazaki M, Horii T, Hata K, et al. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrob Agents Chemother. 2011;55(10):4652–4658.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Watanabe N, Castanheira M, et al. Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods. J Antimicrob Chemother. 2011;66(11):2581–2584.
   PubMed Web of Science ®Google Scholar
• Hata K, Horii T, Miyazaki M, et al. Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis. Antimicrob Agents Chemother. 2011;55(10):4543–4551.
   PubMed Web of Science ®Google Scholar
• Oliver J, Sibley G, Kennedy A, et al. F901318, a novel antifungal agent from the orotomide class: discovery and mechanism of action. Poster 749 Advances Against Aspergillosis 2016.
   Google Scholar
• Oliver JD, Sibley GE, Beckmann N, et al. F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. Proc Natl Acad Sci U S A. 2016;113:12809–12814.
   PubMed Web of Science ®Google Scholar
• Law D, editor. The efficacy of F901318 a novel antifungal drug in an animal model of aspergillosis. Boston MA: ICAAC-American Society for Microbiology; 2016.
   Google Scholar
• Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311–1320.
   PubMed Web of Science ®Google Scholar
• Arthurs B, Wunderle K, Hsu M, et al. Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia. Respir Med Case Rep. 2017;21:27–29.
   PubMed Web of Science ®Google Scholar
• Er Dedekarginoglu B, Savas Bozbas S, Ulubay G, et al. Culture-positive pulmonary aspergillosis infection: clinical and laboratory features of solid-organ transplant recipients. Exp Clin Transplant. 2017;15(Suppl 1):214–218.
   PubMedGoogle Scholar
• Snelders E, van der Lee HA, Kuijpers J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 2008;5(11):e219.
   PubMed Web of Science ®Google Scholar
• Verweij PE, Chowdhary A, Melchers WJ, et al. Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles? Clin Infect Dis. 2016;62(3):362–368.
   PubMed Web of Science ®Google Scholar
• Verweij PE, Lestrade PP, Melchers WJ, et al. Azole resistance surveillance in Aspergillus fumigatus: beneficial or biased? J Antimicrob Chemother. 2016;71(8):2079–2082.
   PubMed Web of Science ®Google Scholar
• Alvarez-Moreno C, Lavergne RA, Hagen F, et al. Azole-resistant Aspergillus fumigatus harboring TR34/L98H, TR46/Y121F/T289A and TR53 mutations related to flower fields in Colombia. Sci Rep. 2017;7:45631.
   PubMed Web of Science ®Google Scholar
• Heo ST, Tatara AM, Jiménez-Ortigosa C, et al. Changes in in vitro susceptibility patterns of Aspergillus to triazoles and correlation with aspergillosis outcome in a tertiary care cancer center (1999-2015). Clin Infect Dis. 2017.
   PubMed Web of Science ®Google Scholar
• Hollomon D. Does agricultural use of azole fungicides contribute to resistance in the human pathogen Aspergillus fumigatus? Pest Manag Sci. 2017;12:412–418.
   Google Scholar
• Denning DW, Bromley MJ. Infectious disease. How to bolster the antifungal pipeline. Science. 2015;347(6229):1414–1416.
   PubMed Web of Science ®Google Scholar
• van de Kant KD, van der Sande LJ, Jöbsis Q, et al. Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic review. Respir Res. 2012;13:117.
   PubMed Web of Science ®Google Scholar
• Röck F, Barsan N, Weimar U. Electronic nose: current status and future trends. Chem Rev. 2008;108(2):705–725.
   PubMed Web of Science ®Google Scholar
• de Heer K, Kok MG, Fens N, et al. Detection of airway colonization by Aspergillus fumigatus by use of electronic nose technology in patients with cystic fibrosis. J Clin Microbiol. 2016;54(3):569–575.
   PubMed Web of Science ®Google Scholar
• Dragonieri S, Pennazza G, Carratu P, et al. Electronic nose technology in respiratory diseases. Lung. 2017;195:157–165.
   PubMed Web of Science ®Google Scholar
• de Heer K, van der Schee MP, Zwinderman K, et al. Electronic nose technology for detection of invasive pulmonary aspergillosis in prolonged chemotherapy-induced neutropenia: a proof-of-principle study. J Clin Microbiol. 2013;51(5):1490–1495.
   PubMed Web of Science ®Google Scholar
• de Heer K, Vonk SI, Kok M, et al. eNose technology can detect and classify human pathogenic molds in vitro: a proof-of-concept study of Aspergillus fumigatus and Rhizopus oryzae. J Breath Res. 2016;10(3):036008.
   PubMed Web of Science ®Google Scholar
• Panackal AA. Combination antifungal therapy for invasive Aspergillosis revisited. Med Mycol Open Access. 2016;2:2.
   PubMedGoogle Scholar
• Ledoux MP, Toussaint E, Denis J, et al. New pharmacological opportunities for the treatment of invasive mould diseases. J Antimicrob Chemother. 2017;72(suppl_1):i48–i58.
   PubMed Web of Science ®Google Scholar
• Katragkou A, Roilides E, Walsh TJ. Can repurposing of existing drugs provide more effective therapies for invasive fungal infections? Expert Opin Pharmacother. 2016;17(9):1179–1182.
   PubMed Web of Science ®Google Scholar
• Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. 2015;162(2):81–89.
   PubMed Web of Science ®Google Scholar
• Caillot D, Thiébaut A, Herbrecht R, et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer. 2007;110(12):2740–2746.
   PubMed Web of Science ®Google Scholar
• Astvad KM, Hare RK, Arendrup MC. Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates. Clin Microbiol Infect. 2017;32:311–319.
   Google Scholar
• Katragkou A, McCarthy M, Meletiadis J, et al. In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds. Antimicrob Agents Chemother. 2014;58(11):6934–6937.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Motyl MR, et al. In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods. Antimicrob Agents Chemother. 2013;57(2):1065–1068.
   PubMed Web of Science ®Google Scholar
• Wring SA, Randolph R, Park S, et al. Preclinical pharmacokinetics and pharmacodynamic target of SCY-078, a first-in-class orally active antifungal glucan synthesis inhibitor, in murine models of disseminated candidiasis. Antimicrob Agents Chemother. 2017;61(4):e02068-16.
   PubMed Web of Science ®Google Scholar
• Wring SA, Randolph R, Park S, et al. SCY-078 a first in class orally active antifungal glucan synthesis inhibitor: pre-clinical pharmacokinetics and pharmacodynamic target in murine models of disseminated candidiasis. Antimicrob Agents Chemother. 2017.
   Web of Science ®Google Scholar
• Mukherjee PK, Sheehan DJ, Hitchcock CA, et al. Combination treatment of invasive fungal infections. Clin Microbiol Rev. 2005;18(1):163–194.
   PubMed Web of Science ®Google Scholar
• Muñoz P, Singh N, Bouza E. Treatment of solid organ transplant patients with invasive fungal infections: should a combination of antifungal drugs be used? Curr Opin Infect Dis. 2006;19(4):365–370.
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Gebremariam T, Luo G, et al. Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins. Antimicrob Agents Chemother. 2011;55(4):1768–1770.
   PubMed Web of Science ®Google Scholar